| REVIEW ARTICLE |
|
| Year : 2011 | Volume
: 1
| Issue : 1 | Page : 12-15 |
|
|
Leber hereditary optic neuropathy - Therapeutic challenges and early promise
Patrick Yu-Wai-Man1, Patrick F Chinnery2
1 Mitochondrial Research Group, Institute of Genetic Medicine, Centre for Life, Newcastle University, Newcastle upon Tyne NE1 3BZ; Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
2 Mitochondrial Research Group, Institute of Genetic Medicine, Centre for Life, Newcastle University, Newcastle upon Tyne NE1 3BZ; Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
Correspondence Address:
Patrick Yu-Wai-Man
Institute of Genetic Medicine, Centre for Life, Newcastle University, Newcastle upon Tyne NE1 3BZ
UK
 Source of Support: None, Conflict of Interest: None  | 5 |
DOI: 10.1016/j.tjo.2011.09.001
|
|
|
Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) disorder in the general population. It is an important cause of severe, usually irreversible, visual loss among young adults with a peak age of onset in the second and third decades of life. Management is currently mostly supportive but recent developments in LHON research are pointing the way towards more effective treatments for this blinding mitochondrial disorder.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
